Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 3 of 3

Full-Text Articles in Medicine and Health Sciences

Comparative Survival Of Asian And White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel, Susan Halabi, Sandipan Dutta, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Ian M. Thompson Jr., Kim N. Chi, Johann S. De Bono, John C. Araujo, Christopher Logothetis, Mario A. Eisenberger, David I. Quinn, Karim Fizazi, Michael J. Morris, Celestia S. Higano, Ian F. Tannock, Eric J. Small, William Kevin Kelly Jan 2020

Comparative Survival Of Asian And White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel, Susan Halabi, Sandipan Dutta, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Ian M. Thompson Jr., Kim N. Chi, Johann S. De Bono, John C. Araujo, Christopher Logothetis, Mario A. Eisenberger, David I. Quinn, Karim Fizazi, Michael J. Morris, Celestia S. Higano, Ian F. Tannock, Eric J. Small, William Kevin Kelly

Mathematics & Statistics Faculty Publications

There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castration-resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with docetaxel and prednisone (DP) or a DP-containing regimen. Individual participant data from 8820 men with mCRPC randomly assigned on nine phase III trials to receive DP or a DP-containing regimen were combined. Men enrolled in these trials had a diagnosis of prostate adenocarcinoma. The median overall survival was 18.8 months (95% confidence interval [CI] = 17.4 to 22.1 months) and 21.2 months (95% …


Classification Models Of Idiopathic Pulmonary Fibrosis Patients, Mohammed Alqawba, Luis R. Rodriguez, Norou Diawara, Rebecca T. Beuschel, Maryann Kaler, Amisha V. Barochia, Stewart J. Levine, Steven D. Nathan, Geraldine Grant Jan 2020

Classification Models Of Idiopathic Pulmonary Fibrosis Patients, Mohammed Alqawba, Luis R. Rodriguez, Norou Diawara, Rebecca T. Beuschel, Maryann Kaler, Amisha V. Barochia, Stewart J. Levine, Steven D. Nathan, Geraldine Grant

Mathematics & Statistics Faculty Publications

Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal interstitial lung disease with no current cure. Progression of IPF is difficult to predict as the clinical course can be highly variable and range from a rapidly deteriorating state to a relatively stable state, or may be characterized by a slow progressive decline. Therefore, the need for an accurate diagnosis and improved tools for monitoring and managing IPF is of paramount importance, all for understanding the mitochondrial structure and the function played in the IPF. Mitochondrial DNA copy number (MtDCN) has been correlated with mortality in IPF patients and is a …


Quantifying The Varying Predictive Value Of Physical Activity Measures Obtained From Wearable Accelerometers On All-Cause Mortality Over Short To Medium Time Horizons In Nhanes 2003-2006, Lucia Tabacu, Mark Ledbetter, Andrew Leroux, Ciprian Crainiceanu, Ekaterina Smirnova Jan 2020

Quantifying The Varying Predictive Value Of Physical Activity Measures Obtained From Wearable Accelerometers On All-Cause Mortality Over Short To Medium Time Horizons In Nhanes 2003-2006, Lucia Tabacu, Mark Ledbetter, Andrew Leroux, Ciprian Crainiceanu, Ekaterina Smirnova

Mathematics & Statistics Faculty Publications

Physical activity measures derived from wearable accelerometers have been shown to be highly predictive of all-cause mortality. Prediction models based on traditional risk factors and accelerometry-derived physical activity measures are developed for five time horizons. The data set contains 2978 study participants between 50 and 85 years old with an average of 13.08 years of follow-up in the NHANES 2003–2004 and 2005–2006. Univariate and multivariate logistic regression models were fit separately for five datasets for one- to five-year all-cause mortality as outcome (number of events 46, 94, 155, 218, and 297, respectively). In univariate models the total activity count (TAC) …